title: Prognosis value of mitotic kinase Aurora-A for primary duodenal adenocarcinoma.
abstract: Others and we have demonstrated that hypoxia-inducible factor 1α (HIF-1α) and transcriptionally upregulated Aurora-A are required for disease progression in several tumors. We investigated the clinicopathological value of HIF-1α and Aurora-A in primary duodenal adenocarcinoma (PDA). Using immunohistochemistry, we evaluated Aurora-A and HIF-1α expression semiquantitatively in 140 PDA cases. There were 76 cases from one institute that formed the training set; 64 cases from another two institutes were used as the testing set to validate the prognostic value of Aurora-A and HIF-1α expression. Aurora-A expression was high or sufficient in the tumor zone, whereas expression was low in the adjacent normal epithelia. High Aurora-A expression, identified using the training set receiver operator characteristic (ROC) analysis-generated cutoff score, predicted poorer overall survival both in the testing set (18.0 vs. 45.1 %, P = 0.001) and training set (23.1 vs. 53.9 %, P = 0.011). Multivariate Cox regression confirmed that Aurora-A was an independent prognostic factor. Contrary to previous studies, we did not detect any correlation between Aurora-A and HIF-1α. Survival analysis showed that HIF-1α level was not correlated with patient outcome (P = 0.466). Activation of Aurora-A, an independent negative prognostic biomarker, might be used to identify particular PDA patients for more selective therapy.
authors.affiliation: Department of Medical Oncology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510630, China.
authors.forename: Jie
authors.initials: J
authors.lastname: Chen
authors.forename: Qu
authors.initials: Q
authors.lastname: Lin
authors.forename: Jing-Yun
authors.initials: JY
authors.lastname: Wen
authors.forename: Xing
authors.initials: X
authors.lastname: Li
authors.forename: Xiao-Kun
authors.initials: XK
authors.lastname: Ma
authors.forename: Xin-Juan
authors.initials: XJ
authors.lastname: Fan
authors.forename: Qin-Hua
authors.initials: QH
authors.lastname: Cao
authors.forename: Min
authors.initials: M
authors.lastname: Dong
authors.forename: Li
authors.initials: L
authors.lastname: Wei
authors.forename: Zhan-Hong
authors.initials: ZH
authors.lastname: Chen
authors.forename: Xiao-Yun
authors.initials: XY
authors.lastname: Li
authors.forename: Tian-Tian
authors.initials: TT
authors.lastname: Wang
authors.forename: Quentin
authors.initials: Q
authors.lastname: Liu
authors.forename: Xiang-Bo
authors.initials: XB
authors.lastname: Wan
authors.forename: Yan-Fang
authors.initials: YF
authors.lastname: Xing
authors.forename: Xiang-Yuan
authors.initials: XY
authors.lastname: Wu
mesh_terms: D000230:Adenocarcinoma / Q000175:diagnosis / Q000201:enzymology*; D064096:Aurora Kinase A / Q000378:metabolism*; D014408:Biomarkers, Tumor / Q000378:metabolism*; D015153:Blotting, Western; D004379:Duodenal Neoplasms / Q000175:diagnosis / Q000201:enzymology*; D005260:Female; D006801:Humans; D051795:Hypoxia-Inducible Factor 1, alpha Subunit / Q000378:metabolism; D007150:Immunohistochemistry / Q000706:statistics & numerical data; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011379:Prognosis; D016016:Proportional Hazards Models; D012372:ROC Curve
chemical_list: D014408:Biomarkers, Tumor; D051795:Hypoxia-Inducible Factor 1, alpha Subunit; D064096:Aurora Kinase A